Malignant melanoma: genetics and therapeutics in the genomic era
Top Cited Papers
Open Access
- 15 August 2006
- journal article
- review article
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 20 (16) , 2149-2182
- https://doi.org/10.1101/gad.1437206
Abstract
Cell for cell, probably no human cancer is as aggressive as melanoma. It is among a handful of cancers whose dimensions are reported in millimeters. Tumor thickness approaching 4 mm presents a high risk of metastasis, and a diagnosis of metastatic melanoma carries with it an abysmal median survival of 6–9 mo. What features of this malignancy account for such aggressive behavior? Is it the migratory history of its cell of origin or the programmed adaptation of its differentiated progeny to environmental stress, particularly ultraviolet radiation? While the answers to these questions are far from complete, major strides have been made in our understanding of the cellular, molecular, and genetic underpinnings of melanoma. More importantly, these discoveries carry profound implications for the development of therapies focused directly at the molecular engines driving melanoma, suggesting that we may have reached the brink of an unprecedented opportunity to translate basic science into clinical advances. In this review, we attempt to summarize our current understanding of the genetics and biology of this disease, drawing from expanding genomic information and lessons from development and genetically engineered mouse models. In addition, we look forward toward how these new insights will impact on therapeutic options for metastatic melanoma in the near future.Keywords
This publication has 344 references indexed in Scilit:
- Lipocalin-type prostaglandin D synthase as a melanocyte marker regulated by MITFBiochemical and Biophysical Research Communications, 2006
- Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factorsEuropean Journal Of Cancer, 2005
- Functional and therapeutic significance of Akt deregulation in malignant melanomaCancer and Metastasis Reviews, 2005
- Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naeviPublished by Elsevier ,2005
- Contribution of the SgIGSF adhesion molecule to survival of cultured mast cells in vivoBiochemical and Biophysical Research Communications, 2004
- Peptide vaccine trials for melanoma: preclinical background and clinical resultsSeminars in Cancer Biology, 2003
- The Hallmarks of CancerCell, 2000
- Microphthalmia-Associated Transcription Factor Interacts with PU.1 and c-Fos: Determination of Their Subcellular LocalizationBiochemical and Biophysical Research Communications, 1999
- Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTENCell, 1998
- Analysis ofras mutations in human melanocytic lesions: activation of theras gene seems to be associated with the nodular type of human malignant melanomaZeitschrift für Krebsforschung und Klinische Onkologie, 1995